More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.51B
EPS
0.52
P/E ratio
27.1
Price to sales
4.48
Dividend yield
--
Beta
0.301857
Previous close
$14.73
Today's open
$14.31
Day's range
$14.31 - $14.64
52 week range
$9.77 - $16.33
show more
CEO
Johnny Cheng
Employees
1790
Headquarters
Hong Kong,
Exchange
Nasdaq Global Select
Shares outstanding
174465524
Issue type
American Depository Receipt
Healthcare
Pharmaceuticals
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2027 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements.
GlobeNewsWire • Nov 16, 2026

HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript
HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript
Seeking Alpha • Nov 12, 2026

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —
GlobeNewsWire • Nov 5, 2026

HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress —
GlobeNewsWire • Nov 2, 2026

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia — — Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition — — Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the US Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding.
GlobeNewsWire • Oct 29, 2026

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —
GlobeNewsWire • Oct 26, 2026

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on Thursday, November 5, 2026, at 4:30 pm HKT / 8:30 am GMT / 3:30 am EST.
GlobeNewsWire • Oct 27, 2026

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO ® —
GlobeNewsWire • Oct 26, 2026

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc (“GSK”) has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.
GlobeNewsWire • Oct 21, 2026

ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill
ADP publishes the jobs data Wall Street watches every month, but its own payroll counts now tell a different story about where the labor market is actually heading.
24/7 Wall Street • Oct 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell HUTCHMED (China) Limited commission-free¹. Build wealth for the long term using automated trading and transfers.